Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Farmaci > Onco > Flashcards

Onco Flashcards

1
Q

TRASTUZUMAB

A

Anti-HER2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

PERTUZUMAB

A

Anti HER2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

LAPATINIB

A

Anti HER2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

T-DM1

A

Anti HER2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

CETUXIMAB

A

Anti EGFR (HER1)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

PANITUMUMAB

A

Anti EGFR (HER1)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

ERLOTINIB

A

Anti EGFR (HER1)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

GEFITINIB

A

Anti EGFR (HER1)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

AFATINIB

A

Anti EGFR (HER1)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

OSIMERTINIB

A

Anti EGFR (HER1)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Categoria di ALECTINIB, CRIZOTINIB, CERITINIB, BRIGATINIB, LORLATINIB

A

Anti ALK

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

VEMURAFENIB

A

Anti BRAF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

DABRAFENIB

A

Anti BRAF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

ENCORAFENIB

A

Anti BRAF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

TRAMETINIB

A

Anti MEK

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

COBIMETINIB

A

Anti MEK

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

BEVACIZUMAB

A

Anti VEGF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

AFLIBERCEPT

A

Anti VEGFR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

RAMUCIRUMAB

A

Anti a VEGFR

20
Q

SOTORASIB e ADAGRASIB

A

Anti KRAS G12C

21
Q

EVEROLIMUS

A

Inibitore di mTOR

22
Q

TEMSIROLIMUS

A

Inibitori di mTOR

23
Q

PALBOCICLIB

A

Inibitori delle kinasi ciclina-dipendenti

24
Q

RIBOCICLIB

A

Inibitori delle kinasi ciclina-dipendenti

25
Q

ABEMACICLIB

A

Inibitori delle kinasi ciclina-dipendenti

26
Q

OLAPARIB

A

PARP inhibitors

27
Q

NIRAPARIB

A

PARP Inhibitors

28
Q

RUCAPARIB

A

PARP Inhibitors

29
Q

PEMIGATINIB

A

Anti FGFR

30
Q

ERDAFITINIB

A

Anti FGFR

31
Q

SUNITINIB

A

TKI ad azione multipla

32
Q

SORAFENIB

A

TKI ad azione multipla

33
Q

IMATINIB

A

TKI ad azione multipla

34
Q

PAZOPANIB

A

TKI ad azione multipla

35
Q

CABOZANTINIB

A

TKI ad azione multipla

36
Q

AXITINIB

A

TKI ad azione multipla

37
Q

REGORAFENIB

A

TKI ad azione multipla

38
Q

LENVATINIB

A

TKI ad azione multipla

39
Q

IPILIMUMAB

A

Anti CTLA 4 (immunoterapia passiva)

40
Q

NIVOLUMAB

A

Anti PD 1 dei linfociti (immunoterapia passiva)

41
Q

PEMBROLIZUMAB

A

Anti PD 1 dei linfociti (immunoterapia passiva)

42
Q

CEMIPLIMAB

A

Anti PD 1 dei linfociti (immunoterapia passiva)

43
Q

ATEZOLIZUMAB

A

Anti PD L1 del microambiente tumorale (immunoterapia passiva)

44
Q

AVELUMAB

A

Anti PD L1 del microambiente tumorale (immunoterapia passiva)

45
Q

DURVALUMAB

A

Anti PD L1 del microambiente tumorale (immunoterapia passiva)

46
Q

RELATLIMAB

A

Anti LAG 3 dei linfociti (immunoterapia passiva)

47
Q

IFOSFAMIDE

A

Mostarde azotate (alchilanti)

Farmaci (2 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions